Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s): MEDXF

Healthcare

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

TSX:MDP - Post by User

Medexus Pharmaceuticals Inc > Primed & ready

<< Previous

Bullboard Posts

Next >>

Comment by oceanelevenon Feb 22, 2021 11:55am

111 Views

Post# 32626647

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Primed & ready

High 5.. I strongly believe we will make huge gains here...Bio tech/pharma stocks are going to shine this year along with 5g and commodities....you gotta buy low and sell high....I think we got a good price today and if it flirts in the 7.50's I will grab more shares....I would luv to see the financials soon as I believe they will be very good..They have everything aligned to send this paper up up and away..I call that a "MELT UP"....we are in a good place Rockafellow!!!

<< Previous

Bullboard Posts

Next >>

Apolo IV Acquisition and Marviken Ontario sign merger agreement